MedTrace Logo

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

NCT03097328 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2024-04-29

Study results available
· View outcomes & findings →

Summary

This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma. The intervention involved in this study is TAK-228.

Conditions

Interventions

DRUG

TAK-228

TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth

Sponsors & Collaborators

  • Calithera Biosciences, Inc

    collaborator INDUSTRY

  • Bradley A. McGregor, MD

    lead OTHER

Principal Investigators

  • Bradley McGregor, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2021-07-20
Completion
2024-04-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03097328 on ClinicalTrials.gov